AdvisorShares Investments LLC Grows Stock Position in Chemed Corporation $CHE

AdvisorShares Investments LLC grew its holdings in shares of Chemed Corporation (NYSE:CHE) by 10.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 959 shares of the company’s stock after purchasing an additional 89 shares during the quarter. AdvisorShares Investments LLC’s holdings in Chemed were worth $467,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CHE. Kayne Anderson Rudnick Investment Management LLC increased its holdings in Chemed by 2.6% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 597,175 shares of the company’s stock worth $367,454,000 after acquiring an additional 15,041 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of Chemed by 3.9% in the first quarter. Neuberger Berman Group LLC now owns 521,212 shares of the company’s stock worth $320,712,000 after purchasing an additional 19,650 shares during the period. Boston Trust Walden Corp increased its stake in shares of Chemed by 0.4% in the second quarter. Boston Trust Walden Corp now owns 247,434 shares of the company’s stock worth $120,483,000 after purchasing an additional 1,083 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Chemed by 9.7% in the first quarter. Dimensional Fund Advisors LP now owns 218,675 shares of the company’s stock worth $134,547,000 after purchasing an additional 19,421 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Chemed by 3.4% in the first quarter. Northern Trust Corp now owns 215,523 shares of the company’s stock worth $132,616,000 after purchasing an additional 6,988 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the sale, the chief executive officer directly owned 96,197 shares in the company, valued at $44,373,752.16. This trade represents a 3.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nicholas Michael Westfall sold 10,012 shares of the firm’s stock in a transaction on Monday, August 4th. The stock was sold at an average price of $421.91, for a total value of $4,224,162.92. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,162 shares of company stock valued at $5,677,511 in the last three months. Corporate insiders own 3.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CHE. Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Saturday, July 5th. Bank of America reduced their price objective on shares of Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Royal Bank Of Canada reduced their price objective on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and upped their price target for the stock from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Finally, Oppenheimer dropped their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $578.50.

Chemed Stock Performance

NYSE CHE opened at $454.24 on Friday. The company has a market capitalization of $6.62 billion, a P/E ratio of 24.02, a P/E/G ratio of 2.69 and a beta of 0.43. The stock has a 50 day moving average price of $448.27 and a 200-day moving average price of $494.63. Chemed Corporation has a one year low of $408.42 and a one year high of $623.60.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The company had revenue of $624.90 million during the quarter, compared to the consensus estimate of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.64 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts predict that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.